Krystal drives NORC’s health care evaluation work by bringing sharp clinical pharmacist expertise in guideline interpretation, specialty therapies, and real‑world evidence. As a subject matter expert on the Medicare Drug Price Negotiation Support project, she translates complex clinical standards into clear, actionable evaluation criteria that reflect how care is delivered in practice. Her background in drug utilization management, formulary strategy, and payer policy allows her to assess access, safety, and effectiveness for high‑cost therapies across diverse patient populations. Krystal excels at distilling dense clinical evidence into practical decision frameworks, identifying nuance in oncology and specialty care, and grounding analytic work in real‑world workflows to ensure that findings are clinically meaningful and decision‑ready.

At NORC, Krystal contributes to guideline abstraction, evidence synthesis, and clinical logic development for pathway and utilization evaluations. She maps clinical concepts to data elements, reviews medication access and utilization measures, and strengthens outcome definitions with clinical precision. Krystal also advises on prior authorization requirements, formulary exceptions, and specialty‑drug considerations that affect interpretation. Her work enhances the clinical integrity, clarity, and usefulness of deliverables for clients, ensuring alignment with clinical and regulatory standards.

Prior to joining NORC, Krystal served as a senior clinical oncology pharmacist in medical affairs at CVS Health, where she developed utilization management criteria, led specialty pipeline monitoring, and presented clinical recommendations to pharmacy and therapeutics (P&T) committees and executive leadership. She also held oncology pharmacist roles at various Chicagoland area health care institutions, leading drug utilization reviews, building treatment protocols, supporting multidisciplinary care, and guiding therapy access. Krystal remains a practicing pharmacist at the University of Chicago Medicine, where she has provided inpatient, ambulatory, and infusion support since 2015. Board‑certified in pharmacotherapy (BCPS), her clinical depth spans oncology, hematology, rare disease, rheumatology, neurology, gastroenterology, immunology, and infectious disease.

Krystal's leadership experience includes serving as president of the Chicago Pharmacists Association, contributing to national advisory boards, and presenting on oncology, access, and health equity. As a board member with Onyx 360 NFP, Krystal helps deliver health education, screenings, and resources to underserved communities across Chicago. She is also deeply committed to mentorship, guiding pharmacy students who represent the future of her profession—further grounding her evaluation work in real‑world practice, community impact, and equity‑focused care.

Some of Krystal’s notable work includes expert commentary on the product profile of tislelizumab for advanced esophageal cancer, published in Oncology (2024). She also contributed to scholarship addressing health equity and disparities in oncology care, including “Black Pain in America: How Black Patients Experience Gaps in Care Due to Disparities in Our Healthcare System,” published in Oncolytics Today (2022), co-authored with Randall Knoebel. Earlier, she co-authored “A Statewide Professional Pharmacy Approach to Raising Awareness of Diversity, Equity, and Inclusion in Pharmacy,” presented at the Illinois Council of Health-System Pharmacists Spring Meeting (2021) alongside Charlene Hope and David Martin.

Krystal is also an active professional speaker whose presentations focus on oncology care delivery, health equity, and emerging therapies. Her speaking engagements include, “Operationalizing SDOH Strategies in Oncology Workflow” at a Network for Collaborative Oncology Development & Advancement (NCODA) continuing education webinar (2025); “Health Equity and Leveling Access to Cancer Care” at the Hematology Oncology Pharmacy Conference Midwest (HOPCON-MW) (2025); and a keynote address for the P1 Student White Coat Ceremony at Chicago State University College of Health Sciences and Pharmacy (2025). She has also delivered lectures on sickle cell disease for Midwestern University’s Clinical Pharmacotherapeutics course (2023) and presented on evolving treatment approaches in “Sickle Cell Disease Treatment: A New Era” for the Illinois Council of Health-System Pharmacists continuing education program (2022) and “Breakthroughs in Sickle Cell Treatment & Management” for an MD Newsline webcast (2022). Earlier presentations include “Disparities in Chronic Pain Management” for the NCODA PQI Podcast (2022) and “The Programmed Cell Death Pathway: An Overview of PD-1 and PD-L1 Targeted Cancer Immunotherapy” for NCODA student education talks (2022).